Ansell FY18 – Value to soon emerge

Ansell reported FY18 earnings with 5% revenue growth and 15% increase in NPAT. This represented the mid point of guidance

FY19 looks a little more challenging, as the outlook is likely to disappoint on higher raw material cost growth.

We will watch for the next Algo Buy signal,  as it is likely the market will over react and a discounted entry opportunity will soon present.

ANN goes ex-div $0.25 on the 24th August.

 

EVN – Algo Update

Evolution Mining reported FY18 earnings in line with consensus with revenue of $1.5b, EBITDA $795m, EBIT $360 and NPAT of $250m. 

FY19 production guidance 720k-770k ounces at an expected all in cost $880oz. EVN was one of the lowest cost gold producers over FY18.

EVN declared a fully franked 2HFY18 dividend of 4c. On a full year basis into FY19, we have EVN on a 2.8% yield.

We see EVN as a buy opportunity within the $2.50 to $2.75 price range. Supported by a rebound in the oversold gold price.

 

OZ Minerals – earnings review

Our Algo Engine generated a buy signal recently in OZL, the stock is a current holding within our ASX100 model. We see current share price support near $8.50.

OZL announced its 1HCY18 earnings last week, with revenue reported at $534m, EBITDA $290m and net earnings $220m.

The numbers were slightly below market expectations, however,  diversification of its future production base and extended mine life extensions at Prominent Hill, should underpin future earnings growth.

On a forward basis, we have OZL trading on a 2.5% yield into FY19.

 

 

Downer EDI confirms growth expectations

Our Algo Engine generated a buy signal in Downer EDI back in June at $6.60, with the stock price now pushing $8.00, most of the good news is priced in.

The FY18 earnings were announced on Thursday and the numbers were in line with consensus expectations. The highlight is the forward guidance of 13% growth.

FY18 NPATA came in at $296 & FY19 guidance now sits at $335m. This places Downer EDI on a forward yield of 4%.

Buy Healthscope

Healthscope report earnings on Tuesday and the market is looking for NPAT to increase to $170m. We’re expecting the FY19 outlook statement to support the share price.

Technically, HSO has now filled the price gap to $2.08

 

Australian Banks & Credit Quality

We continue to watch the lower high formations in the Australian bank names and expect the current rally to soon run into Resistance.

Low revenue growth, restructuring costs, and reduced product and regional footprint will cap earnings. We’re also watching credit quality data across credit cards, motor vehicle sales and home loans.

Trends within the Australian residential mortgage 90+ day past due loans, as a percentage of residential mortgage exposure-at-default, was mostly flat from the prior quarter. NAB’s Pillar 3 release shows only a slight uptick, whereas CBA’s result last week showed a greater increase in home loan 90+ day arrears.

There are some pockets of stress in the mortgage books, primarily in WA.

ETF covering Australian banks shows a retest of the recent highs.

Where as the ETF covering global banks shows a pronounced lower high formation.